In Brief: Pharmacy antitrust suit
Executive Summary
Pharmacy antitrust suit: Tentative settlement agreement should be ready for May 16 Chicago federal court hearing. Pharmacy groups opposed to original $409 mil. no-injunction settlement offer are prepared to support new proposal. The 15 manufacturers involved in the first settlement attempt are understood to be renegotiating with plaintiffs, although all have not yet approved final language. The revised settlement is likely to include some form of injunctive relief for pharmacies regarding access to volume-driven discounts, based on Judge Kocoras' April 4 recommendations ("The Pink Sheet" April 8, p. 3)...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: